Integral Diagnostics (IDX) H1 2025 earnings summary

Executive summary

• Revenue for 1H FY25 increased 9.3% year-over-year to $252.9m, including $3.5m from Capitol Health post-acquisition on 20 December 2024.

• Standalone revenue grew 7.8% to $249.4m, with operating EBITDA up 8.2% to $46.8m and operating NPAT up 31.9% to $9.8m.

• Completed merger with Capitol Health, expanding the network to 150 clinics and over 350 radiologists, with integration progressing and at least $10m in annual pre-tax net cost synergies targeted, most realized in the first year.

• Declared a fully franked interim dividend of 2.5 cents per share, with a payout ratio of 106.1% of operating NPAT on a merged basis.

• Served over 600,000 patients and performed 1.3 million exams in the half, with strong Net Promoter Scores in Australia (+83) and New Zealand (+79).

Financial highlights

• Total revenue and other income rose to $253.4m from $231.6m year-over-year.

• Operating EBITDA margin was 18.8%, up slightly from 18.7% year-over-year.

• Free cash flow increased 22.7% to $29.4m, with conversion (pre-replacement capex) at 88.8%.

• Net debt increased to $298.7m, mainly due to the Capitol acquisition, with net debt/EBITDA at 2.8x (2.6x including synergies), and $138.8m liquidity headroom.

• Operating diluted EPS up 14.2% to 3.6 cents per share.

Outlook and guidance

• Focus on integrating Capitol Health, targeting at least $10m in annual pre-tax net cost synergies, most within the first year.

• FY25 replacement and growth capex expected at $60-65m, including $20m for Capitol.

• Positioned to benefit from MRI deregulation and National Lung Cancer Screening Program starting July 2025.

• Strategic priorities include organic growth, operational improvements, teleradiology, digital, and AI initiatives.